Vortioxetine for depression treatment in hospital setting: experience from a single psychiatric hospital

The study was conducted to assess the possibility of using vortioxetine for the treatment of depressive disorders in a hospital setting. Material and methods: 32 patients with depressive disorders of various etiologies were included. Patients were assessed using Clinical Global Impression scale and Hamilton Depression Rating Scale HDRS-17 at the beginning of the study and in dynamics. Mean HDRS-17 value at the beginning was 20.1±6.6. According to the etiology of depressive disorders patients were divided into three groups: endogenous disorders—17, organic depressions—11, reactive states—4. Patients were followed-up for 60 days. Results. Vortioxetine was used both as first line treatment and after previous therapy, 10 to 20 mg a day. In 7 patients (21,9%) therapy was discontinued due to adverse events or worsening of condition. The remaining 25 patients (78,1%) showed positive dynamics. Patients with depression with psychotic features (n = 18) were assessed separately: in 5 patients therapy was discontinued, in the remaining 13 people positive dynamics were noted. Conclusion. The study has demonstrated high efficacy of vortioxetine when prescribed for the treatment of depressive disorders, including psychotic depression, in a hospital setting. The drug was well tolerated in the majority of patients.

1. Любов Е.Б., Ястребов В.С., Шевченко Л.С., Чапурин С.А., Чурилин Ю.Ю., Былим И.А., Гажа А.К., Доронин В.В., Косов А.М., Петухов Ю.Л., Фадеев П.Н. Экономическое бремя шизофрении в России // Социальная и клиническая психиатрия. 2012; 22:36-42.

2. Гурович И.Я., Любов Е.Б., Саркисян Г.Р. и соавт. Стоимость лечения эпилепсии в психиатрических службах России // Проблемы стандартизации в здравоохранении. 2004; 11:72.

3. Гурович И.Я., Любов Е.Б., Чапурин С.А., Чурилин Ю.Ю. и соавт. Стоимостной анализ депрессивных расстройств в отечественных психиатрических службах // Журнал неврологии и психиатрии им. С.С. Корсакова. 2010: 3:77–82.

4. Лиманкин О.В., Спикина А.А., Парфенов Ю.А., Отмахов А.П. Оценка эффективности ведения больных параноидной шизофренией в стационарном и амбулаторном звене // Социальная и клиническая психиатрия. 2016; 26:32-37.

5. Gustavsson А., Svensson M., Jacobi F. et al. Cost of disorders of the brain in Europe 2010 // Eur. Neuropsychopharmacol. 2011; 21:718–779.

6. Alvarez E. et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder // International Journal Neuropsychopharmacol. 2012; 15:589-600.

7. Katona C., Hansen T., Olsen C.K. et al. A randomized, double-blind, placebo-controlled, duloxetinereferenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder // International Clinical Psychopharmacology. 2012; 27:215–223.

8. Шагиахметов Ф.Ш., Анохин П.К., Шамакина И.Ю. Вортиоксетин: механизмы мультимодальности и клиническая эффективность // Социальная и клиническая психиатрия. 2016; 26:84-96.

9. Незнанов Н.Г., Мазо Г.Э., Рукавишников Г.В. Влияние антидепрессантов на когнитивные функции пациентов с депрессивным расстройством//Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2015; 3:75- 82.